Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 6/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.65 |
| ▸ | CA2 | P00918 | 3/20 | 0.65 |
| ▸ | PLK1 | P53350 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10972044 | 0.86 | NPC1 (0.73) | PKMNPC1RAB9ACA1CA2 | |
| SCHEMBL16685001 | 0.85 | NPC1 (0.83) | PKMNPC1RAB9ACA1CA2 | |
| SCHEMBL10576894 | 0.83 | MAPT (0.63) | PKMNPC1RAB9ACA1CA2 | |
| SCHEMBL8598019 | 0.83 | NPC1 (0.69) | PKMNPC1RAB9ACA1CA2 | |
| SCHEMBL4155602 | 0.83 | NPC1 (0.69) | PKMNPC1RAB9ACA1CA2 | |
| SCHEMBL6500947 | 0.81 | KDM4E (0.67) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL11370186 | 0.81 | NPC1 (0.67) | PKMNPC1RAB9ACA1CA2 | |
| SCHEMBL13113851 | 0.81 | PKM (1.00) | PKMNPC1RAB9ACA1CA2 | |
| SCHEMBL11755990 | 0.80 | NPC1 (1.00) | PKMNPC1RAB9ACA1CA2 | |
| SCHEMBL15595417 | 0.80 | KDM4E (0.70) | PKMNPC1RAB9ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825338-B2 | SELECTIVE FUNCTIONALIZATION OF OLIGONUCLEOTIDES WITH CONJUGATE GROUPS WITHOUT THE NEED FOR POST-SYNTHETIC LABELING; SOLID PHASE SYNTHESIS; DEBLOCKING AN ACID LABILE HYDROXYL GROUP AND REACTING WITH A PHOSPHORAMIDITE | ISIS PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20040077019-A1 | Tagging compounds and process for use in aida libraries | GSTACH HUBERT (AT) | 2004-04-22 | — | — | US | disclosed |
| EP-1379541-A1 | LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR | ISIS Pharmaceuticals, Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030208061-A1 | Labeled oligonucleotides, methods for making same, and compounds useful therefor | ISIS PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1332135-A1 | TAGGING COMPOUNDS AND PROCESS FOR USE IN AIDA LIBRARIES | Novartis AG (CH) | 2003-08-06 | — | — | EP | disclosed |
| EP-0922050-B1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002079216-A1 | LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002036575-A1 | TAGGING COMPOUNDS AND PROCESS FOR USE IN AIDA LIBRARIES | NOVARTIS AG (CH) | 2002-05-10 | — | — | WO | disclosed |
| US-6215001-B1 | ANTIINFLAMMATORY AGENTS, ANTIASTHMATICS, AND ANTIALLERGENS; SIDE EFFECT REDUCTION | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-04-10 | — | — | US | disclosed |
| WO-2000055179-A1 | NOVEL PHOSPHATE AND THIOPHOSPHATE PROTECTING GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-6031109-A | Phenoxy-, phenylthio-, benzoyl-alkyleneaminoalkylene-imidazole derivatives as therapeutic agents | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| CN-1224426-A | 3-descladinose-2, 3-anhydroerythromycin derivatives | ABBOTT LAB (US) | 1999-07-28 | — | — | CN | disclosed |
| EP-0922050-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5780642-A | NON-STEROIDAL ANTIINFLAMMATORY AGENT WHICH BLOCKS RELEASE OF ARACHIDONIC ACID FROM PHOSPHOLIPIDS; SIDE EFFECT REDUCTION | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-07-14 | — | — | US | disclosed |
| US-5750510-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997042205-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0705251-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000493-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
| EP-0154190-A1 | Pyridones | MERCK PATENT GmbH (DE) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208061-A1 | Labeled oligonucleotides, methods for making same, and compounds useful therefor | METTL16, BCDIN3D, GARS1 | PKM 3799/4885NPC1 3108/4885RAB9A 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.